Figure 4.

BIX enhanced anticancer effect by autophagic flux. WT SGC‐7901 cells and Beclin‐1 KO SGC‐7901 (Beclin‐1 KO) cells were pretreated with 1 μM BIX for 2 hr then treated with 5 μM Cis for 12 hr. (a) Effects of Beclin‐1 knockout by using CRISPR‐Cas9 technology in SGC‐7901 cell line. (b) Western blot analysis of conversion of LC3B‐I to LC3B‐II. (c) LDH release. (d) GSDME‐F, GSDME‐N, and Cleaved CASP3 were detected by western blot in WT SGC‐7901 cells and Beclin‐1 KO SGC‐7901 cells. (e) Cell viability. (e,g) Tumor volume after the treatment of BIX and Cis. (h,i) The representative image of tumor. Data are presented as mean ± SD and at least three separate experiments in all studies. ***p < .001 compared with control, ^### p < .001 compared with WT BIX + Cis group. GSDMD‐N, GSDMD‐N terminal; GSDME, gasdermin E; GSDME‐F, full‐length GSDME; LDH, lactate dehydrogenase